BiVictriX Therapeutics PLC
LSE:BVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its Industry Average (3.9), the stock would be worth GBX0 (100% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | GBX10 |
0%
|
| Industry Average | 3.9 | GBX0 |
-100%
|
| Country Average | 0 | GBX0 |
-100%
|
Forward EV/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
BiVictriX Therapeutics PLC
LSE:BVX
|
8.3m GBP | 0 | -3.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
348.9B USD | 6.7 | 84.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.4B USD | 6.1 | 24 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.5B USD | 5.9 | 18.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 8.5 | 27.7 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 4 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 10.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
63.6B AUD | 3.4 | 30.3 |
Market Distribution
Other Multiples
BiVictriX Therapeutics PLC
Glance View
BiVictriX Therapeutics Plc focuses on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer. The company is headquartered in Alderley Edge, Cheshire and currently employs 5 full-time employees. The company went IPO on 2021-08-11. The firm has developed Bi-Cygni technology, which focuses on an area of unmet medical need. The firm utilizes Bi-Cygni therapeutics, which are designed to selectively target antigen co-expression fingerprints, or twin antigens, on tumour cells, which are absent from healthy cells. The firm has developed Bi-Cygni technology which utilizes Antibody Drug Conjugates, an existing class of potent biological drugs, for the treatment of various cancers including Acute Myeloid Leukaemia. The Company’s Bi-Cygni product candidate, BVX001, which is in early stage development for the treatment of acute myeloid leukaemia (AML). The firm has a diverse panel of cancer-specific twin antigens, across a range of cancer indications that include Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm.
